Biotech Values

[DewDiligence]

Sadly, it also adds to a large body of evidence that many long-time FDA employees wouldn't see the appearance of conflict of interest if it co-authored a journal article with them. They do the rest of the Agency a grave disservice in the public arena.

What should the FDA have done differently, IYO, in the way it went about solving the contaminated-heparin problem? Would it have made any consequential difference if Dr. Woodcock and other FDA staffers had omitted their names from the published papers describing the scientific process by which the integrity of the heparin supply was restored?